Citations

Citations to this article as recorded by  

• Improving quality in IBD – Evaluation of corticosteroid excess prescription trends and its predictive role in disease-related outcomes
  José Damasceno, Tânia Carvalho, Bruno Arroja, João Soares, Sofia Mendes, Bruno Gonçalves, Ana Rebelo, Raquel Gonçalves, Tiago Leal
  Gastroenterología y Hepatología.2026; : 502716.     CrossRef
• Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use
  Jung Min Moon, Kyoung-Eun Kwon, Ju Won Lee, Kyung Rok Minn, Kyuwon Kim, Jeongkuk Seo, Seung Yong Shin, Sun-Young Jung, Chang Hwan Choi
  Digestive and Liver Disease.2025; 57(1): 176.     CrossRef
• Inflammatory bowel disease in Africa: the current landscape of pharmacological treatments and the promise of emerging innovations
  Murtada A. Oshi
  Exploration of Drug Science.2025;[Epub]     CrossRef
• Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease
  Shilpa Sharma
  Intestinal Research.2025; 23(3): 254.     CrossRef
• Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting
  Luca Degli Esposti, Valentina Perrone, Diego Sangiorgi, Stefania Saragoni, Melania Dovizio, Flavio Caprioli, Fernando Rizzello, Marco Daperno, Alessandro Armuzzi
  Digestive and Liver Disease.2024; 56(1): 29.     CrossRef